Who
Sheryle Bolton
Director
Company insider
Files Form 4 as: Director, Tivic Health Systems; Director, Live Ventures; Director, Bridge Capital.
In numbers
- Trades disclosed
- 19
- Buys
- 2
- Sells
- 0
- Bought
- $45K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 19 May 2008
- Last trade
- 15 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Apr 2026filed 20 Apr 2026 | Tivic Health SystemsBiotechnology | SEC FORM 4 Bought | $10K10,000 at $1.04 | filing |
| 15 Apr 2026filed 20 Apr 2026 | VBIO Valion BioBiotechnology | SEC FORM 4 Bought | $10K10,000 at $1.04 | filing |
| 6 Aug 2025filed 8 Aug 2025 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 Aug 2024filed 13 Aug 2024 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Jun 2022filed 21 Jun 2022 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 14 Dec 2021filed 16 Dec 2021 | VBIO Valion Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 1 Feb 2012filed 8 Feb 2012 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $1,002188 at $5.33 | filing |
| 1 Feb 2012filed 7 Feb 2012 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $1,354254 at $5.33 | filing |
| 3 Jan 2012filed 6 Jan 2012 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $3,8341,131 at $3.39 | filing |
| 1 Dec 2011filed 7 Dec 2011 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $3,8343,067 at $1.25 | filing |
| 1 Nov 2011filed 8 Nov 2011 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $3,8102,381 at $1.60 | filing |
| 1 Oct 2011filed 20 Oct 2011 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $3,8342,396 at $1.60 | filing |
| 1 Sep 2011filed 12 Oct 2011 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | $3,8342,296 at $1.67 | filing |
| 1 Oct 2008filed 22 Jan 2009 | LIVE Live VenturesRetail — Specialty | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 May 2008filed 20 May 2008 | Bridge Capital | SEC FORM 4 Bought | $4,521300 at $15.07 | filing |
| 19 May 2008filed 20 May 2008 | Bridge Capital | SEC FORM 4 Bought | $20K1,300 at $15.10 | filing |
News
Valion Bio, Inc. Common Stock (NASDAQ:VBIO) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ComparisonVBIO · themarketsdaily.com · 18 Oct 2026Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New ...VBIO · pr-inside.com · 9 Oct 2026Valion Bio, Inc.: Valion Bio: Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data CentersVBIO · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Sheryle Bolton; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.